Edgewise Therapeutics, Inc. (EWTX) Stock Analysis

Q: What is the EWTX stock price target?

Take-profit $35.74 (+17.6% upside). Prior stop was $29.32.

Q: What are the risks of investing in EWTX?

Concentration risk — Product: sevasemten and EDG-7500; Quality below floor (1.6 < 4.0); Value-trap signals (2/5): High leverage (D/E 9.3), Material insider selling (14 sells, 0.18% of cap); Quality below floor (1.6 < 4.0); Value-trap signals (2/5): High leverage (D/E 9.3), Material insider selling (14 sells, 0.18% of cap).

Q: Is EWTX overvalued or undervalued?

Edgewise Therapeutics, Inc. trades at a P/E of N/A (forward -13.0). TrendMatrix value score: 7.5/10. Overall verdict: Sell.

Q: What do analysts say about EWTX?

18 analysts cover EWTX with a consensus score of 4.2/5. Average price target: $41.

SellVALUE-TRAP 2/5Moderate ConfidenceUpdated 2026-04-30

Healthcare · Biotechnology

Earnings in 7 days (2026-05-07). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Edgewise Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for rare muscle diseases. Lead candidates are sevasemten (muscular dystrophies, pivotal trial ongoing) and EDG-7500 (hypertrophic cardiomyopathy). The company has no approved... Read more

$30.43+17.6% A.UpsideScore 5.0/10#76 of 158 Biotechnology

Stop $29.32Target $35.74(analyst − 13%)A.R:R 1.8:1

Analyst target$41.08+35.0%12 analysts

$35.74our TP

$30.43price

$41.08mean

$20

$51

Sell if holding. Engine safety override at $30.43: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 1.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.0/10, moderate confidence.

Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: aggressive.

Thesis

Rewards

No bull case signals

Risks

Concentration risk — Product: sevasemten and EDG-7500

Quality below floor (1.6 < 4.0)

Value-trap signals (2/5): High leverage (D/E 9.3), Material insider selling (14 sells, 0.18% of cap)

Key Metrics

P/E (TTM)—

P/E (Fwd)-13.0

Mkt Cap$3.3B

EV/EBITDA-14.5

Profit Mgn0.0%

ROE-34.2%

Rev Growth—

Beta0.25

DividendNone

Rating analysts18

Quality Signals

Piotroski F4/9

Options Flow

P/C0.14bullish

IV94%elevated

Max Pain$12-60.6% vs spot

Concentration Risks(10-K Item 1A)

HIGHProductsevasemten and EDG-7500
10-K Item 1A: 'We are substantially dependent on the success of our lead product candidates, sevasemten and EDG-7500'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value7.515%1.13

Quality1.615%0.24

Growth5.015%0.75

Momentum4.410%0.44

Sentiment7.110%0.71

Insider Activity3.810%0.38

Peer Rank5.110%0.51

Technical Setup8.85%0.44

Risk Profile4.25%0.21

Catalyst4.35%0.21

Overall (Σ contributions)5.02

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe

0.0

Roa

0.0

Gross Margin

0.0

Operating Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Piotroski F

4.4

Current Ratio

5.0

Moat

5.0

Cash-burning (FCF negative)No competitive moatQuality concerns

GatesMomentum 4.4<4.5EARNINGS PROXIMITY 7d<=7dA.R:R 1.8 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARSuitability: Aggressive

RSI

37 · Neutral

↓ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $30.23Resistance $35.00

Price Targets

$29

$36

A.Upside+17.4%

A.R:R1.8:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (1.6 < 4.0)

! Value-trap signals (2/5): High leverage (D/E 9.3), Material insider selling (14 sells, 0.18% of cap)

! Momentum score 4.4/10 — below 4.5 minimum

Earnings

2/4 beats

Next Earnings2026-05-07 (7d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is EWTX stock a buy right now?

Sell if holding. Engine safety override at $30.43: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 1.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $29.32. Score 5.0/10, moderate confidence.

What is the EWTX stock price target?

Take-profit target: $35.74 (+17.6% upside). Prior stop was $29.32. Stop-loss: $29.32.

What are the risks of investing in EWTX?

Concentration risk — Product: sevasemten and EDG-7500; Quality below floor (1.6 < 4.0); Value-trap signals (2/5): High leverage (D/E 9.3), Material insider selling (14 sells, 0.18% of cap).

Is EWTX overvalued or undervalued?

Edgewise Therapeutics, Inc. trades at a P/E of N/A (forward -13.0). TrendMatrix value score: 7.5/10. Verdict: Sell.

What do analysts say about EWTX?

18 analysts cover EWTX with a consensus score of 4.2/5. Average price target: $41.

What does Edgewise Therapeutics, Inc. do?Edgewise Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for rare muscle...